HC Wainwright & Co. Reiterates Buy on Janux Therapeutics, Maintains $70 Price Target
Benzinga Newsdesk 11 months ago
NewsPrice TargetReiterationAnalyst Ratings
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Janux Therapeutics (NASDAQ:JANX) with a Buy and maintains $70 price target.
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Janux Therapeutics (NASDAQ:JANX) with a Buy and maintains $70 price target.